OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Crohns & Colitis is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
OP05 Outcome of induction therapy with vedolizumab in children: Results from the prospective, multi-centre VEDOKIDS study	225
P750 Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National U.S. Cohort of U.S. Military Veterans with Inflammatory Bowel Disease	200
P139 Inflammatory bowel disease and impairment of working life	192
P222 Chronic pain is common in Paediatric Inflammatory Bowel Disease and impacts quality of life	191
OP32 The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo	110
P709 Endoscopic healing and clinical remission after administration of adalimumab to patients with Crohn’s disease of the small intestine	88
P833 Cervical cancer risk in newly diagnosed ulcerative colitis: a nationwide population-based study	86
P501 Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohort	85
P905 Predictive pharmacogenetic risk of pancreatitis in Inflammatory Bowel Disease patients treated with thiopurines: a case-control study from the ENEIDA registry	81
P127 Inflammatory Bowel Disease-associated colorectal cancers: retrospective cohort study from a tertiary centre surveillance programme over 10 years	81
P113 Protein fingerprint biomarkers of collagen remodeling can evaluate fibrogenesis in an in vitro colonic scar-in-a-jar model	78
P149 Novel capillary blood point-of-care test for adalimumab and infliximab trough levels: Effects of abnormal blood conditions on the test result	76
P310 Smoking is not an independent risk factor for surgery in patients with Crohn’s Disease on biologic therapy	72
P294 Assessment of Fatigue and Associated Factors in Patients with Inflammatory Bowel Disease: A Questionnaire-based Study	64
P358 Long-term clinical outcomes of intestinal Behçet’s disease: a 30-year cohort study at a tertiary hospital in South Korea	59
P324 Long-term impact of the COVID-19 pandemic on Inflammatory Bowel Disease healthcare utilization: A two-year nationwide update	55
P308 A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: SOUL study	55
P674 Predictors of response to biologics in Crohn’s Diseases: A population-based study from the epi-IIRN	53
P616 Safety of COVID-19 vaccines in patients with IBD	53
DOP88 Long-term real-world data of ustekinumab in Crohn’s Disease – the Stockholm ustekinumab study – STOCUSTE	50
P483 Patient-reported quality of life, anxiety, and depression associated with switching originator infliximab to biosimilar	49
P089 Colonic explant lactate concentration and inflammatory protein secretion in ulcerative colitis	49
P171 PSC/IBD and IBD have similar type and location of colonic lesions, but Dye ChromoEndoscopy (DCE) increases detection rate compared to White Light Endoscopy (WLE)	46
P212 The Impact of Crohn’s Disease in Patients with Colorectal Cancer: A Danish Nationwide Cohort Study, 2009-2019	46
P601 Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with Propensity Score adjustment: maintenance phase results from the prospective observational R	45

P051 IFNγ-macrophages could mediate EMT in Crohn’s disease through the WNT pathway	44
P719 Identification of differentially expressed genes between AIEC and non-AIEC clinical isolates during in vitro cell infection	44
P513 Treatment persistence in bio-naive patients with long-standing Crohn’s disease treated with first-line biologics: real-life data from a Croatian tertiary center	44
OP14 Interpreting genome-wide association studies of Inflammatory Bowel Disease through the lens of single-cell sequencing	44
P132 An audit of quality of histopathology reporting of colorectal mucosal biopsies for the diagnosis and assessment of Inflammatory Bowel Disease	43
P301 Relapse rates after withdrawal of thiopurines in patients with Inflammatory Bowel Disease	43
P368 Safety issues of azathioprine in patients with inflammatory bowel disease: clinical experience from a referral center	40
P570 Prevalence and risk factors for intestinal resection in patients with Crohn’s disease in a Greek referral center	40
P187 Major Depression in patients with Ulcerative Colitis and its relationship with clinical activity	40
P708 Ileal involvement defined by Montreal classification in Crohn’s disease is associated with a distinct microbial composition in ileal and colonic mucosa	40
P277 Assessment of fatigue as a patient-reported outcome: Correlation with baseline disease activity and therapy response in Inflammatory Bowel Disease	40
P454 Evaluation of the nutritional care status in italian centers managing patients affected by inflammatory bowel disease	39
P0279 Assessing patient-reported health status in moderate-to-severe Crohn’s Disease and Ulcerative Colitis: Results from the communicating needs and features of IBD experiences (CONFIDE) survey	39
Corrigendum to: ECCO CONFER Investigators, Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series	39
P0435 Comparative analysis between capsule endoscopy and ileocolonoscopy for activity detection in ileal Crohn’s disease. Preliminary results from the CAPITER study, a multicenter study from the Young	39